trending Market Intelligence /marketintelligence/en/news-insights/trending/YTr4_ZUNc2feFVnXVS2n8w2 content esgSubNav
In This List

La Jolla Pharmaceutical plans $100M public offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


La Jolla Pharmaceutical plans $100M public offering

La Jolla Pharmaceutical Co. said it is planning a registered offering of $100 million of its common shares.

The underwriter has a 30-day option to buy up to $15 million of the company's common shares.

Cowen is acting as sole book-running manager for the offering.

San Diego-based La Jolla plans to use proceeds from the offering for general corporate purposes, including the continued commercialization of blood pressure drug Giapreza as well as funding its ongoing and future clinical trials of LJPC-401, the company's proprietary formulation of a synthetic hormone.